Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated
05:33pm, Wednesday, 11'th Oct 2023
Eli Lilly is expected to receive FDA approval for tirzepatide, an obesity medication, and has two other medications in phase 3 clinical studies. The GLP-1 therapy market is projected to reach $150 bil
Why Eli Lilly Stock Is Jumping Today
11:45am, Wednesday, 11'th Oct 2023
Novo Nordisk announced it's stopping a kidney outcomes trial for Ozempic earlier than planned. Investors are hoping that Novo Nordisk's positive development will translate to success for Lilly.
Ozempic Is Moving a Bunch of Stocks Wednesday Morning
09:37am, Wednesday, 11'th Oct 2023
Markets were poised to move higher again on Wednesday morning. Shares of Novo Nordisk climbed on good news from a study of its drug Ozempic on kidney patients.
Eli Lilly gets $14bn boost from Ozempic data - here's what's happened
08:53am, Wednesday, 11'th Oct 2023
Eli Lilly and Co (NYSE:LLY) shares were trading 2.6% higher pre-market after a positive read-across from a key trial read-out from its main rival in the weight-loss market. Denmark's Novo Nordisk (NYS
Dialysis company shares plunge after Ozempic trial success vs. kidney trouble
03:59am, Wednesday, 11'th Oct 2023
The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.
Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus
12:47pm, Tuesday, 10'th Oct 2023
The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.
Why Eli Lilly Stock Crawled Higher Today
06:24pm, Monday, 09'th Oct 2023
According to the results of a recent survey, inclusion of weight-loss drugs is set to ramp up dramatically. More than a few businesses plan to include such coverage in their healthcare insurance polic
Cramer says Vertex has a drug that may address the 'largest market opportunity in the world'
10:18am, Monday, 09'th Oct 2023
CNBC's Jim Cramer said investors keep an eye on Vertex Pharmaceuticals (VRTX) as the company develops a non-opioid pain drug.
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
07:19am, Monday, 09'th Oct 2023
Although healthcare stocks lag other sectors, large-cap leaders such as Eli Lilly & Co. NYSE: LLY, McKesson Corp. NYSE: MCK and Novartis AG NYSE: NVS are in possible buy ranges as they get moving-
Rate Watching And Why The Bond Market Matters
04:00pm, Sunday, 08'th Oct 2023
The bond market and interest rates were the biggest news items of the week. The absolute level of the 10-year bond rate is causing havoc in various sectors, such as housing and commercial real estate.
3 Biotech Stocks Ready to Break Out in 2024
09:00am, Saturday, 07'th Oct 2023
While the S&P 500 remains up on the year, the biotech sector is down. Even though the broader market is showing signs of strength in areas like AI and automation, those trends haven't benefited biotec
3 No-Brainer Growth Stocks to Buy in October
06:53am, Saturday, 07'th Oct 2023
Eli Lilly is crushing the market because of its impressive product lineup and strong prospects. Novo Nordisk is just getting warmed up with a massive opportunity for Ozempic and Wegovy.
Eli Lilly pipeline of obesity treatments is positioned to pay off beyond just Mounjaro, analysts say
03:01pm, Friday, 06'th Oct 2023
Shares of Eli Lilly and Co (NYSE:LLY) rose Friday after analysts at Bank of America reaffirmed its confidence in the company. The firm reiterated its Buy rating and upped its price target to $700 from
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
10:31am, Friday, 06'th Oct 2023
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not
08:15am, Friday, 06'th Oct 2023
Ozempic and Mounjaro are key drugs for Novo Nordisk and Eli Lilly, respectively. Both treat most of the same conditions, and both are major drivers of earnings.
